Tumor-initiating activity of the beta-blocker ZAMI 1305 in the liver of the female Wistar rat.
A 1-week treatment with the hepatocarcinogen beta-blocker DL-1-(2-nitro-3-methyl-phenoxy)-3-tert-butylamino-propan-2-ol (ZAMI 1305) induces the appearance of preneoplastic liver lesions--oval cell hyperplasia, basophilic and gamma-glutamyltranspeptidase positive (GGT+) foci--in female Wistar rats, as evidenced by the Solt and Farber short-term test of carcinogenesis. ZAMI 1305-treatment also induces liver DNA damage, as evaluated by alkaline sucrose gradient analysis. The data suggest that the oncogenic B-blocker ZAMI 1305 has initiating activity in the liver of the female Wistar rat.
D015073:2-Acetylaminofluorene / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000633:toxicity*; D000818:Animals; D004247:DNA / Q000378:metabolism; D005260:Female; D006498:Hepatectomy; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008114:Liver Neoplasms, Experimental / Q000139:chemically induced* / Q000473:pathology; D009929:Organ Size / Q000187:drug effects; D011230:Precancerous Conditions / Q000139:chemically induced / Q000473:pathology; D011412:Propanolamines / Q000633:toxicity*; D051381:Rats; D011919:Rats, Inbred Strains
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; C028475:ZAMI 1305; D004247:DNA; D015073:2-Acetylaminofluorene